RETRACTED: Gene-expression patterns predict phenotypes of immune-mediated thrombosis (Retracted article. See vol. 118, pg. 4497, 2011)

被引:33
作者
Potti, A [1 ]
Bild, A
Dressman, HK
Lewis, DA
Nevins, JR
Ortel, TL
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA
[2] Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA
[3] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27710 USA
[4] Duke Hemostasis & Thrombosis Ctr, Durham, NC USA
关键词
D O I
10.1182/blood-2005-07-2669
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid antibody syndrome (APS) is a complex autoimmune thrombotic disorder with defined clinical phenotypes. Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complications, the severity of these potential events mandates aggressive and extended lifelong antithrombotic therapy. One hundred twenty-nine patients (57 patients with APS and venous thromboembolism [VTE], 32 patients with VTE without aPLA, 32 patients with aPLA only, and 8 healthy patients) were enrolled. RNA from peripheral-blood collection was used for DNA microarray analysis. Patterns of gene expression that characterize APS as well as thrombosis in the presence of aPLA were identified by hierarchical clustering and binary regression methods. Gene-expression profiles identify and predict individuals with APS from patients with VTE without aPLA. Importantly, similar methods identified expression profiles that accurately predicted those patients with aPLA at high risk for thrombotic events. All profiles were validated in independent cohorts of patients. The ability to predict APS, but more importantly, those patients at risk for venous thrombosis, represents a paradigm for a genomic approach that can be applied to other populations of patients with venous thrombosis, providing for more effective clinical management of disease, while also reflecting the possible underlying biologic processes.
引用
收藏
页码:1391 / 1396
页数:6
相关论文
共 36 条
  • [1] ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE ANALYSIS OF 500 CONSECUTIVE PATIENTS
    ALARCONSEGOVIA, D
    DELEZE, M
    ORIA, CV
    SANCHEZGUERRERO, J
    GOMEZPACHECO, L
    CABIEDES, J
    FERNANDEZ, L
    DELEON, SP
    [J]. MEDICINE, 1989, 68 (06) : 353 - 365
  • [2] BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629
  • [3] DRESSMAN HK, MICROARRAY GENE EXPR
  • [4] Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow
    Field, SL
    Hogg, PJ
    Daly, EB
    Dai, YP
    Murray, B
    Owens, D
    Chesterman, CN
    [J]. BLOOD, 1999, 94 (10) : 3421 - 3431
  • [5] ANTICARDIOLIPIN ANTIBODIES (ACA) DIRECTED NOT TO CARDIOLIPIN BUT TO A PLASMA-PROTEIN COFACTOR
    GALLI, M
    COMFURIUS, P
    MAASSEN, C
    HEMKER, HC
    DEBAETS, MH
    VANBREDAVRIESMAN, PJC
    BARBUI, T
    ZWAAL, RFA
    BEVERS, EM
    [J]. LANCET, 1990, 335 (8705) : 1544 - 1547
  • [6] Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome
    Galli, M
    Barbui, T
    [J]. BLOOD, 1999, 93 (07) : 2149 - 2157
  • [7] Antiphospholipid antibodies and thrombosis
    Greaves, M
    [J]. LANCET, 1999, 353 (9161) : 1348 - 1353
  • [8] HARRIS EN, 1983, LANCET, V2, P1211
  • [9] Heit JA, 2001, THROMB HAEMOSTASIS, V86, P452, DOI 10.1161/ATVBAHA.108.162545
  • [10] Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916